Chembio Diagnostics (CEMI) Stock Price
Chembio Diagnostics Price
Revenue has compounded at 16.1% per year over the past 18 years to 48.34 M USD. Earnings per share have declined at 31.6% per year over the last 10 years. Chembio Diagnostics's net margin stands at -48.2%, down from -23.5% several years earlier.
Chembio Diagnostics stock price
Chembio Diagnostics business model & stock analysis
Frequently asked questions about Chembio Diagnostics
Chembio Diagnostics Inc, a leading biotechnology company, operates with a unique business model focusing on the development, manufacturing, and commercialization of diagnostic solutions. The company specializes in point-of-care testing, providing rapid diagnostic tests for infectious diseases, including HIV, Syphilis, and Zika. Chembio's business strategy revolves around developing proprietary technologies and collaborations for market expansion. By leveraging their expertise in immunoassays, microfluidics, and lateral flow technologies, Chembio aims to improve global healthcare outcomes through accurate and affordable diagnostic solutions. With an emphasis on innovation and strategic partnerships, Chembio Diagnostics Inc continues to make significant contributions to the diagnostics industry.
Chembio Diagnostics Inc is primarily active in the healthcare industry.
Chembio Diagnostics Inc faces competition from various companies in the market. Some of its main competitors include companies like Abbott Laboratories, Bio-Rad Laboratories, and Quidel Corporation. These companies also operate in the diagnostics industry and offer a range of testing solutions and products, often catering to similar customer needs. Chembio Diagnostics Inc strives to differentiate itself through its innovative technology, product quality, and customer service in order to stay competitive in the market.
Chembio Diagnostics Inc. is a leading company in the field of point-of-care diagnostic tests. Established in 1985, Chembio has been dedicated to developing innovative, rapid, and reliable testing solutions for infectious diseases. With a strong commitment to global health, the company focuses on creating advanced diagnostic assays that provide accurate results within minutes, enabling better patient care and disease management. Chembio has built a diverse portfolio of products, including rapid tests for HIV, malaria, Zika virus, and syphilis, among others. Over the years, Chembio Diagnostics Inc. has become renowned for its expertise, quality products, and contributions to global healthcare.
Chembio Diagnostics Inc has achieved several significant milestones. The company secured FDA approval for its rapid HIV diagnostic tests, which provided accurate and timely results. Chembio also received Emergency Use Authorization (EUA) for its COVID-19 antibody test, allowing for rapid and reliable detection of antibodies in individuals. Additionally, the company expanded its global reach by partnering with various organizations and securing distribution agreements worldwide. Chembio Diagnostics Inc has consistently demonstrated innovation and commitment to delivering high-quality diagnostic solutions, making it a prominent player in the healthcare industry.
Chembio Diagnostics Inc is primarily present in the United States of America.
Chembio Diagnostics Inc represents values such as innovation, quality, and commitment in the field of diagnostic testing. The company focuses on developing and commercializing rapid point-of-care diagnostic tests for infectious diseases, including HIV, Zika, and Ebola. With a strong corporate philosophy centered around improving patient outcomes and global health, Chembio Diagnostics Inc strives to provide accurate and reliable diagnostic solutions. Their advanced technologies and extensive expertise empower healthcare professionals to make informed decisions for early detection and efficient management of various medical conditions. Through continuous research and development, Chembio Diagnostics Inc remains dedicated to delivering efficient and effective diagnostic solutions to healthcare systems worldwide.
6 analysts currently rate the Chembio Diagnostics stock: 0 recommend buying, 3 holding and 3 selling.
The Chembio Diagnostics share (CEMI) is listed on 1 stock exchanges, including: NASDAQ (CEMI).
Chembio Diagnostics Inc. is a company specialized in the development and marketing of rapid tests for infectious diseases. The company is headquartered in Hauppauge, New York, and also operates a production facility in Germany. Chembio Diagnostics' business model is based on offering fast, reliable, and cost-effective diagnostic tests that help doctors and medical professionals detect and treat infectious diseases. The company offers test products for various infections such as HIV, hepatitis C, syphilis, malaria, and dengue fever. Chembio Diagnostics has three main business areas: development, production, and distribution of diagnostic tests. In the development area, the company works intensively on developing new and innovative tests for infectious diseases. The company has its own research and development department that collaborates closely with scientists and industry experts to develop new technologies and products. In the production area, Chembio Diagnostics operates a production facility in Germany where diagnostic tests are manufactured. The company has state-of-the-art technologies and facilities to ensure high quality and production efficiency. The marketing of diagnostic tests is the third business area of Chembio Diagnostics. The company works closely with distributors in different countries to sell its products worldwide. Additionally, the company has distribution agreements with major pharmaceutical companies and medical institutions to promote the spread of its tests. Chembio Diagnostics' products are intended for both medical professionals and patients. The tests are frequently used in medical practices, clinics, and hospitals to diagnose and monitor infections. Additionally, the company also offers rapid tests for field use that can be used by emergency services and doctors in remote areas. Chembio Diagnostics positions itself as a leading provider of rapid tests for infectious diseases and is committed to improving the health of people worldwide. The company continues to invest in research and development to develop innovative products that meet the needs of doctors and patients. Overall, Chembio Diagnostics has built a successful business model based on providing high-quality diagnostic tests for infectious diseases. The company has increased its revenue and global presence and continues its success story.
The revenue cannot currently be calculated for Chembio Diagnostics.
The profit cannot currently be calculated for Chembio Diagnostics.
The P/E ratio cannot be calculated for Chembio Diagnostics at the moment.
The P/S cannot be calculated for Chembio Diagnostics currently.
The Eulerpool Quality Score for Chembio Diagnostics is 3/10.
The ISIN of Chembio Diagnostics is US1635722093. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Chembio Diagnostics is A1JY4D. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Chembio Diagnostics is CEMI. The ticker symbol is used to trade Chembio Diagnostics shares on the stock exchange.
Chembio Diagnostics stock
Chembio Diagnostics Peer Group
Chembio Diagnostics Ticker
Chembio Diagnostics FIGI
All fundamentals and in-depth analysis of Chembio Diagnostics
Our stock analysis for Chembio Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chembio Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.